ShigETEC
Shigellosis and Enterotoxigenic E. coli (ETEC) infection
Phase 2bActive
Key Facts
Indication
Shigellosis and Enterotoxigenic E. coli (ETEC) infection
Phase
Phase 2b
Status
Active
Company
About EveliQure Biotechnologies
Eveliqure Biotechnologies is a private, clinical-stage biotech leveraging a proprietary live attenuated Shigella platform to develop oral vaccines against diarrheal diseases. Its lead candidate, ShigETEC, is in Phase 2b development for shigellosis and ETEC, addressing a significant unmet need in endemic regions and the travel market. The company is led by a seasoned team with deep vaccine development experience and is backed by a strategically experienced board.
View full company profile